Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer
PLOS Biology · 18.06.2026 · 24 (6) · e3003860
DOI: 10.1371/journal.pbio.3003860 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, online erschienen am 18.06.2026. Verfasst von Dario Pasquale Anobile und 17 weiteren Autor:innen. Beteiligte Einrichtung: Innate Immunity in Physiology and Cancer Team, Institut Curie, PSL Research University, INSERM U932, Paris, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Argonaute Proteins, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE European Research Council, Fondation pour la Recherche Médicale, Université de Recherche Paris Sciences et Lettres.
Abstract (Originalsprache)
One of the first-line treatments for advanced non-small cell lung cancer (NSCLC) are immune checkpoint inhibitors (ICI), which activate the antitumor immune response. Despite their success, ICI remain ineffective in many patients, highlighting the need for strategies to overcome resistance. Most efforts have focused on promoting immune cell infiltration into refractory tumors to improve ICI efficacy. In this work, we mobilize this approach by focusing on Argonaute 2 (Ago2), a pivotal member of the RNA interference pathway. Using two murine models of immunorefractory NSCLC, we demonstrate that tumoral Ago2 suppresses interferon signaling, leading to poor immunogenicity and failure of ICI therapy. Genetic deletion of Ago2 in cancer cells restores interferon signaling and supports immune infiltration of the tumor. Consequently, whereas wild-type tumors are resistant to ICI, tumors devoid of Ago2 become sensitive to treatment. In NSCLC patients treated with ICI, high Ago2 expression and a low interferon signature in tumors correlate with reduced survival. Ago2 is thus a driver of the immunorefractory phenotype observed in NSCLC and may represent a therapeutic target when aiming to sensitize patients to ICI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Innate Immunity in Physiology and Cancer Team, Institut Curie, PSL Research University, INSERM U932, Paris, France.
- Translational Immunotherapy Team, Institut Curie, PSL Research University, INSERM U932, Paris, France.
- Department of Translational Research, PSL University, Institut Curie Research Center, Paris, France.
- Department of Diagnostic and Theragnostic Medicine, BioHub, Pathex, Institut Curie Research Center, Paris, France.
- Tolerance and Anti-tumour Immunity Team, Institut Curie, PSL Research University, INSERM U932, Paris, France.
ORCID-Profile: Eliane Piaggio, Enzo Z Poirier
Förderung
- HORIZON EUROPE European Research Council
- Fondation pour la Recherche Médicale
- Université de Recherche Paris Sciences et Lettres
- Fondation Chercher Trouver
- Institut Curie
- Institut National Du Cancer
- Agence Nationale de la Recherche
- Ligue Contre le Cancer
Zitieren
APA
Anobile, D. P., Barbar, L., Maucotel, E., Cornec, A., Manriquez, V., Richer, W., Denizeau, J., Sedlik, C., Bories, C., Couderc, E., Leclere, R., Sobas, J., Papillon, E., Mena Osuna, R., Tosello-Boari, J., Burbage, M., Piaggio, E., & Poirier, E. Z. (2026). Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer. PLOS Biology, 24(6), e3003860. https://doi.org/10.1371/journal.pbio.3003860
Vancouver
Anobile DP, Barbar L, Maucotel E, Cornec A, Manriquez V, Richer W, et al. Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer. PLOS Biology. 2026;24(6):e3003860. doi:10.1371/journal.pbio.3003860
BibTeX
@article{Anobile2026,
author = {Anobile, Dario Pasquale and Barbar, Layla and Maucotel, Emile and Cornec, Alexis and Manriquez, Valeria and Richer, Wilfrid and Denizeau, Jordan and Sedlik, Christine and Bories, Charlie and Couderc, Elodie and Leclere, Renaud and Sobas, Judith and Papillon, Emeline and Mena Osuna, Rafael and Tosello-Boari, Jimena and Burbage, Marianne and Piaggio, Eliane and Poirier, Enzo Z},
title = {Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer},
journal = {PLOS Biology},
year = {2026},
volume = {24},
number = {6},
pages = {e3003860},
doi = {10.1371/journal.pbio.3003860}
}
EUVIMED